Ross J Harris
Biographic Data
| ID | 7446567 |
|---|---|
| NAME | Ross J Harris |
| GIVEN NAMES | Ross J |
| FAMILY NAME | Harris |
| SIGNATURE | HARRIS R J |
| AFFILIATIONS | UK Health Security Agency |
| VERIFIED | No |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 4 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Understanding hepatitis C virus reinfections in England in the context of eliminating viral hepatitis as a public health concern
HCV reinfection appeared to decrease over the study period, but people were most at risk in the year post-treatment, which remained constant over time. Harm reduction services should be accessible to people who inject drugs and people who have been in prison, particularly soon after treatment
Using modelling and public health surveillance data to evidence progress towards the WHO incidence target for hepatitis C elimination in people who inject drugs - a review of complementary approaches …
Analysing HCV incidence trends in people who inject drugs using serial behavioural and seroprevalence data
Fractional polynomials provided an adequate fit with relatively few parameters, but splines may be preferable to ensure flexibility, in particular, to detect short-term changes in the rate of first infection over time that may be a result of treatment effects. Although chronic HCV prevalence has declined with treatment scale up over 2016-2020, there is no evidence yet of a corresponding fall in the rate of first infection. Seroprevalence and risk…
Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK
Real-world evidence showing substantial reductions in chronic HCV associated with increase of HCV treatment scale-up in the community thus supporting the effectiveness of HCV treatment as prevention in people who inject drugs
No prominent works on this page.
Understanding hepatitis C virus reinfections in England in the context of eliminating viral hepatitis as a public health concern
HCV reinfection appeared to decrease over the study period, but people were most at risk in the year post-treatment, which remained constant over time. Harm reduction services should be accessible to people who inject drugs and people who have been in prison, particularly soon after treatment
Using modelling and public health surveillance data to evidence progress towards the WHO incidence target for hepatitis C elimination in people who inject drugs - a review of complementary approaches …
Analysing HCV incidence trends in people who inject drugs using serial behavioural and seroprevalence data
Fractional polynomials provided an adequate fit with relatively few parameters, but splines may be preferable to ensure flexibility, in particular, to detect short-term changes in the rate of first infection over time that may be a result of treatment effects. Although chronic HCV prevalence has declined with treatment scale up over 2016-2020, there is no evidence yet of a corresponding fall in the rate of first infection. Seroprevalence and risk…
Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK
Real-world evidence showing substantial reductions in chronic HCV associated with increase of HCV treatment scale-up in the community thus supporting the effectiveness of HCV treatment as prevention in people who inject drugs
Hepatitis C virus research (4 works) · Hepatitis B Virus Studies (3 works) · Hepatitis C (3 works) · Hepatitis C virus (3 works) · HIV, Drug Use, Sexual Risk (3 works) · Environmental health (2 works) · Incidence (geometry (2 works) · Medicine (2 works) · Public health (2 works) · Advanced Causal Inference Techniques (1 works)